S everal classic risk factors for the development of coronary artery disease (CAD) have been identified. However, these factors may explain only the high prevalence of CAD in part. 1 Injury to the vessel wall and the associated inflammatory response are now generally recognized as essential components of atherogenesis. 2 However, the stimuli that initiate and sustain the inflammatory process have not been fully identified. A candidate trigger of both inflammatory 3 and autoimmune 4 responses is infection, which might be a source of chronic local or systemic inflammation. Several retrospective and cross-sectional studies have shown an association between previous infections with Chlamydia pneumoniae, herpes simplex virus (HSV), cytomegalovirus (CMV), Helicobacter pylori, hepatitis A, or respira-tory tract infection and the presence of CAD or the risk for acute coronary events, but other studies have not shown such an association. [5] [6] [7] [8] The results of prospective studies regarding an association between seropositivity to infectious agents and future cardiac events have also been disparate. 9 -15 Recently, Epstein et al 3 formally introduced the concept of infectious burden and demonstrated that the number of infectious pathogens to which an individual has been exposed is related to the presence of CAD. Zhu and colleagues 16, 17 could show an association between infectious burden and the risk of future cardiac events. Viral infections might differ from bacterial infections regarding their latent state, and Herpesviridae especially exert direct proatherogenic effects on injured vessel walls. 3 In the present study, we prospectively evaluated the impact of the aggregate number of infectious pathogens on long-term prognosis in patients with CAD. Furthermore, the relative contribution of viral and bacterial infections on the long-term outcome and the interaction with an inflammatory process was studied.
Methods

Study Population
Between November 1996 and July 1998, 1018 consecutive patients who had been admitted to the Department of Medicine II of the University Clinic Mainz for diagnostic angiography because of symptoms of suspected CAD and in whom a diameter stenosis of at least 30% was diagnosed in a major coronary artery were included in the present study. Patients with no evidence of CAD as defined above and with evidence of concomitant diseases, in particular, valvular heart disease, cardiomyopathy, known malignant diseases, and febrile conditions, had been excluded. Diabetes mellitus was diagnosed in patients who had previously undergone dietary treatment or received additional oral antidiabetic or insulin medication or who had a current fasting blood sugar level Ͼ125 mg/dL; hypertension was diagnosed in patients who had received antihypertensive treatment or had been diagnosed as hypertensive (blood pressure Ͼ160/90 mm Hg); and hyperlipoproteinemia was diagnosed in patients who had been given lipid-lowering medication or had a history of cholesterol levels Ͼ240 mg/dL. Smoking was classified as current smoking, past smoking (stopped between Ͼ4 weeks and Ͻ40 years ago), or never smoking (never smoked or stopped smoking Ն40 years ago). Acute coronary syndrome was defined as acute myocardial infarction or unstable angina (Braunwald class B or C).
A total of 1010 (99.2%) of the 1018 patients were followed up for a mean of 3.1 (maximum 4.3) years. Patients either presented at our clinic (87.2%) or were interviewed by telephone by trained medical staff. Follow-up information was obtained about death from cardiovascular causes (nϭ78), death from causes not related to heart disease (nϭ22), and nonfatal myocardial infarction (nϭ61). Information about the cause of death or clinical events was obtained from hospital or general practitioner charts.
Study participants had German nationality. The study was approved by the ethics committee of the University of Mainz. Participation was voluntary, and each study subject gave written informed consent.
Infectious Serology and Laboratory Methods
Blood was drawn from all study subjects under standardized conditions after an overnight fasting period before coronary angiography was performed. Samples were stored at Ϫ80°C until analysis.
The serum of each study subject was tested for specific IgG class antibodies against CMV, HSV-1, HSV-2, Epstein-Barr virus (EBV), C pneumoniae, Mycoplasma pneumoniae, Haemophilus influenzae, and H pylori as well as IgA class antibodies against C pneumoniae, M pneumoniae, H pylori, and EBV by using quantitative in vitro ELISA or indirect immunofluorescence (C pneumoniae and H influenzae) (EUROIMMUN). A value of Ͼ20 relative units per mL in the IgG ELISA and a ratio of Ͼ1 in the IgA ELISA were considered positive according to the manufacturer's instructions. Concerning indirect immunofluorescence, the starting dilution was 1:100, and specific fluorescence patterns at or above these dilutions were considered positive. C-reactive protein (CRP) was determined by a highly sensitive, latex particle-enhanced immunoassay (detection range 0 to 20 mg/L, Roche Diagnostics). Lipid serum levels were measured immediately by use of routine methods.
Statistical Considerations
Highest versus lowest pathogen burden groups were compared by 2 test (categorical variables) or Student t test (continuous variables). For skewed distribution (CRP), logarithmically transformed variables were tested. Survival was assessed by Cox regression and the Kaplan-Meier method. For adjusted survival analysis, Cox regression was applied; variables included all univariate predictive variables and those variables possibly confounding or being confounded by infectious serology tested, such as smoking and HDL cholesterol. Adjusted estimates of risks for each unit increase in pathogen burden are presented as hazard risk ratios (HRRs) and 95% CIs. First, pathogen burden was entered as a single ordinal covariate in the Cox regression models; further groups of seropositivities were stratified into low, middle, and high pathogen burden. Additionally, analyses were performed separately for Herpesviridae and bacterial infections. All statistical tests used are reported with 2-tailed probability values; PϽ0.05 was considered to be significant. All computations were carried out by using SPSS, version 10.0. Table 1 demonstrates patient characteristics according to low or high pathogen load. The mean age of the entire study population was 62Ϯ10 years; 73.5% were male patients.
Results
Baseline Characteristics
Univariate Predictors of Mortality From Cardiovascular Causes
As shown in Table 2 , CRP was strongly associated with mortality from cardiovascular causes (HR 1.3 for logarithmically transformed continuous variables, Pϭ0.001). Further univariate predictors were age, history of diabetes, left ventricular ejection fraction, and statin intake at enrollment. Both angiographic features, ie, the number of diseased vessels and the number of stenoses Ͼ30%, were predictors of future fatal cardiovascular events. Interestingly, history of hyperlipidemia paradoxically predicted lower risk after CAD diagnosis. This may be explained by a higher percentage of statin prescription in this patient cohort. Therefore, we preferred to include the variable statin intake instead of history of hyperlipidemia into multivariate analyses. Table 3 demonstrates the associations of baseline pathogen IgG and IgA antibodies with future fatal cardiovascular events. Of all evaluated pathogens, only IgG seropositivity to HSV-2 and IgA seropositivity to EBV as well as H pylori revealed an independent significant association with future cardiovascular death.
Analyses of Seropositivities and Future Death From Cardiac Causes
Pathogen Burden and Future Cardiac Mortality
For analysis of the association between future death from cardiovascular causes and the aggregate number of antipathogen antibodies, we used IgG seropositivities to HSV-1 and -2, CMV, and H influenzae, as well as IgA seropositivities to H pylori, M pneumoniae, C pneumoniae, and EBV. An increasing pathogen burden was significantly predictive of the long-term prognosis in a dose-response manner (PϽ0.0001, fully adjusted) ( Figure 1 ). As demonstrated in Table 4 , relative hazard risk ratios increased with increasing numbers of seropositivities. Because of the limited numbers of subjects with very low and very high pathogen burden, we stratified patients into groups with 0 to 3, 4 or 5, and 6 to 8 numbers of seropositivities. The mortality in these groups amounted to 3.7%, 7.2%, and 12.6%, respectively. In the fully adjusted model, patients seropositive to Ͼ5 pathogens revealed a 5.1 (1.4 to 18.3) increase in risk for future fatal events compared with the reference group of patients with Ͻ4 seropositivities (P for trendϭ0.002, fully adjusted).
Further analyses were performed separating seropositivities into Herpesviridae and bacterial infections ( Table 4 ). The overall dose-response relationship between pathogen burden and future fatal cardiovascular events was mainly driven by seropositivities to Herpesviridae (PϽ0.0001). The hazard risk ratio for individuals with 3 and 4 seropositivities compared with patients with Ͻ2 seropositivities was 6.4 (95% CI 2.1 to 19.6). The corresponding Kaplan-Meier survival estimates to these analyses are presented in Figure 2 .
Pathogen Burden and Combined End Point of Myocardial Infarction and Death From Cardiovascular Causes
The relationship between the combined end point of myocardial infarction and death from cardiovascular causes and total pathogen burden was somewhat attenuated in the fully adjusted model (1.9-fold increase in risk for Ͼ5 compared with Ͻ4 pathogens, 95% CI 1.4 to 18.3). However, the relationship between aggregate number of Herpesviridae and combined end point remained highly significant (2.3-fold increase in risk for Ͼ2 compared with Ͻ2 pathogens, 95% CI 1.2 to 4.4; Pϭ0.008).
Association Between CRP Level, Pathogen Burden, and Future Cardiac Death
To evaluate a possible interaction between pathogen burden, CRP, and future death from cardiovascular causes, we re- All baseline variables as outlined in Table 1 were tested. Cox regression was used; only 1 variable was entered.
*Analyses performed in logarithmically transformed variables (nϭ943).
peated analyses with respect to high (Ͼ0.5 mg/dL) or low (Յ0.5 mg/dL) CRP levels. Figure 3a and 3b demonstrates the association of total pathogen burden with future fatal cardiovascular events, which was independently significant in both subgroups irrespective of the CRP level. Then the association is shown between the aggregate number of seropositivities to bacterial infections (Figure 3c and 3d) or Herpesviridae (Figure 3e and 3f) among both CRP groups. The strongest association between infectious burden and future fatal cardiovascular events was observed for the aggregate number of Herpesviridae among patients with low CRP levels (PϽ0.0001, fully adjusted; HR 5.6, 95% CI 2.3 to 13.9). These data provide evidence that Herpesviridae predict risk independent of CRP, whereas bacterial infections are predictive in patients with elevated CRP levels only.
Discussion
There is consistent evidence that inflammation plays a crucial role in the pathogenesis of atherosclerosis. Inflammatory cell infiltration is observed in atherosclerotic plaques at virtually all stages, and many studies have linked serum markers of inflammation, such as the level of CRP to future cardiac events in healthy individuals as well as in patients with stable or unstable angina. 18, 19 The evidence of infectious pathogens contributing to the atherosclerotic process includes seroepidemiological data, direct identification of Herpesviridae and C pneumoniae in the atherosclerotic plaque, experimental models demonstrating an acceleration of atherosclerosis by Herpesviridae or C pneumoniae, and induction of proatherogenic properties by infectious agents. 3 It is hypothesized that infectious agents exert their effects by inducing a local or systemic inflammatory response and/or by infection-induced autoimmune response involving molecular mimicry.
It has been shown that the aggregate number of pathogens to which an individual had been exposed might be involved in the pathogenesis of atherosclerosis. This concept has been referred to as infectious burden and was demonstrated in a cross-sectional as well as prospective study recently. 3, 16, 17 Increasing numbers of infectious pathogens were associated with future death from overall causes and nonfatal myocardial infarction. This association was described independent of CRP levels.
In the present study, we selected 8 pathogens because of the following 2 main characteristics: They are obligate intracellular pathogens, except for H influenzae and Because of incomplete data of CRP and ejection fraction, total was 795 for the adjusted analyses. *Adjusted for age, sex, presence or absence of ever smoking, diabetes, HDL cholesterol (continuous variable), number of stenoses, invasive treatment, antihypertensive treatment and statin intake at enrollment, CRP (logarithmically transformed continuous variables), and ejection fraction (Ͻ30%). M pneumoniae, and they all develop persistent antibodies targeted to the pathogen. Furthermore, 6 pathogens produce a lifelong latent (Herpesviridae) or persistent infection, whereas H influenzae and M pneumoniae are not known to provoke a persistent infection although they establish a lifelong persistence of antibodies. In all pathogens, we determined anti-IgG antibodies; in some pathogens, additional IgA antibodies were measured because of the nearly 100% prevalence of IgG (EBV) and because of reports suggesting that IgA antibodies might reflect more recent and/or repeated infectious episodes (C pneumoniae, H pylori, and M pneumoniae). 20 The results of the present study confirm and extend previous findings. Three (H pylori, HSV-2, and EBV) of 8 infectious pathogens were identified as being independently predictive of future death from cardiovascular causes. Interestingly, neither IgG nor IgA antibodies to C pneumoniae were associated with future cardiovascular events. It cannot be ruled out that measurement of antibodies to C pneumoniae provides the wrong tool to determine the association between this pathogen and cardiovascular events. However, our data do not support the implicit assumption of several prospective trials testing the effect of macrolide antibiotics on future cardiac event rates in patients with atherosclerosis. 21 On the other hand, our results show for the first time that prior infection to EBV may influence the course of atherosclerosis. EBV is an obligate intracellular pathogen with lifelong persistence in B cells. If infections do play a role in atherogenesis and if, at least in part, infection-induced autoimmune responses contribute to this process, EBV could be a candidate trigger. Virus-induced antigens are part of B-cell membranes and can so far stimulate T-cell activity. On the other hand, EBV-containing T cells have been recently demonstrated in atherosclerotic abdominal aneurysms. 22 Regardless of the mechanism, EBV shows the strongest association of all single pathogens with future events. This may suggest that a variety of pathogens sharing these characteristics may play a role in atherogenesis.
Most important, increasing numbers of infectious serologies were identified as independent risk factors for future cardiac death. Furthermore, stratified analyses in patients with low and high CRP levels demonstrated that the association of pathogen burden with future cardiovascular death remained independently significant in both groups.
We further performed stratified analyses of 2 infectious groups, Herpesviridae and bacterial infections. The aggregate number of Herpesviridae (herpes burden) was highly significantly predictive of future cardiovascular events irrespective of the CRP level. In contrast, the aggregate number of bacterial infections only showed an association with fatal events in patients with an elevated CRP level. These results may provide further evidence that at least the obligate intracellular Herpesviridae having a latent state may contribute to the atherogenic process independent of an inflammatory response. On the other hand, several prospective studies have revealed contradictory results. 9, 12, 14, 23 These disparate results may have been reached for several reasons: In contrast to the present study, each of these studies was restricted to a highly homogeneous, apparently healthy population. Despite the advantage of such highly selected populations (eg, elimination of various confounders), these populations may not necessarily represent other populations (eg, those with proven atherosclerotic disease). Furthermore, most of these studies determined only IgG antibodies, and last, evaluation of Herpesviridae was mostly restricted to anti-CMV IgG alone.
Although prospective in design, the present study shares the limitations of nonrandomized observational studies, ie, unsuspected selection biases and possible confounding. However, the association of infectious burden and mortality remained stable after adjustment for multiple potentially confounding variables. Nonetheless, the present study cannot unequivocally prove a causal relationship between infectious agents and the atherosclerotic process.
In conclusion, our data provide strong evidence that infections play a role in atherogenesis, at least as covariates to preexisting CAD risk factors. An increasing pathogen load (infectious burden) was independently related to future death from cardiovascular causes in patients with CAD. Because there is growing evidence that a variety of pathogens are participating in the development and/or acceleration of at least preexisting atherosclerosis (even by secondary immune or autoimmune mechanisms), it seems questionable whether specific antibiotic therapy to 1 or 2 specific pathogens will be useful in determining the infectious hypothesis and in improving patient outcome. Figure 2 . Kaplan Meier curves for number of seropositivities according to total pathogen burden as described in Figure 1 stratified into low (0 to 2), middle (3 or 4), and high (5 to 8) pathogen load (top); bacterial infections stratified (C pneumoniae, M pneumoniae, H influenzae, and H pylori) into 0 to 1, 2, and 3 or 4 seropositivities (middle); and Herpesviridae (HSV-1, HSV-2, CMV, and EBV) stratified into 0 to 1, 2, and 3 or 4 seropositivities (bottom). 
